Citations

Clear

100 citation(s) found for "Shukla, R".

Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study
Warner, David, Jeng, Bennie H., Kim, Jiyu , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Meyer, Jay J. , Lu, Ying , Twi-Yeboah, Alberta , Lopez-Jimenez, Carlos, Laury, Sarah, Cohen, Elisabeth J. , Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Hood, Christopher , Sugar, Alan M., Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad, Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, M.L. , Barron, Bruce, Hindman, Holly B. , Wise, Ronald E. , Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, A., Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John, Ingraham, Herbert J., Guibord, Nathalie M, Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., Forstot, S. Lance, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Patel, Ravi , Ashe, Sanda, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, Michael A., Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Rullo, Jacob, Johnson, Davin , Mah, Dean, Benson, Matthew , Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Lin, Charles C. , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly, Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Sharma, Vikas, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Niederer, Rachael L. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Perez-Quinones, Victor L, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Edmund, Tsui, Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Keenan, Jeremy David , Hamrah, Pedram , Lee, Hyunjoo, Barbato, John D, Weikert, Mitchell P. , Hood, Christopher, Woodward, Maria A. , Sugar, Alan, Shtein, Roni Mintz , Prescott, Christina R. , Haberman, Ilyse D. , Schrack, Katie E, Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Shieh, Christine , Thorne, George, Sivaraman, Kavitha, Lin, Amy , Repine, Karen, Asbell, Penny A. , Ashe, S, Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Hassonlou, Mojgan, Yung, C.–W., Svanda, Kerri, Keppol, Stacy, Vyas, Neil M, McHam, Lisa, Veena, Mathew, Goshe, Jeffrey M. , Miller, Darby D. , Ma, Jeffrey H

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 277

10.1001/jamaophthalmol.2024.6113 | PMID 40048191 Get It

Importance Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care. Objective To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, severity, and duration of postherpetic neuralgia compared with placebo at 12 and 18 months in participants with herpes zoster ophthalmicus (HZO). Design, Setting, and Participants Multicenter, placebo-controlled randomized clinical trial including 527 immunocompetent, nonpregnant adults with history of HZO rash, documented keratitis, or iritis within 1 year and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater. The study was conducted at 95 participating sites (in Canada, New Zealand, and the US) from November 2017 to June 2024 and participant visits occurred every 3 months. Intervention Treatment with 1000 mg/d of valacyclovir or placebo for 12 months. Main Outcomes and Measures Prevalence of postherpetic neuralgia, severity as determined by pain score (a score of ≥3 on a scale of 1-10), pain duration (≥3 months after HZO onset), and total daily dose of pain medication. Results Of the 527 participants (490 completed 12 months of treatment and 460 completed 18 months), 73 (14%) had postherpetic neuralgia and were analyzed by age at HZO onset (<60 years or ≥60 years) and disease duration (recent [<6 months] or chronic [≥6 months]). Of the 73 participants with postherpetic neuralgia (34 in the valacyclovir group and 39 in the placebo group), the mean age was 62.4 years (SD, 13.6 years), 59% were female, 5% were Black or African American, and 10% were Hispanic. The prevalence of postherpetic neuralgia at 12 months was not reduced by valacyclovir (12/32 [38%]) compared with placebo (14/35 [40%]) (between-group difference, 2.5% [95% CI, −20.8% to 25.8%]; P >.99). The participants who were younger than 60 years at HZO onset and had a chronic disease duration had lower pain scores in the valacyclovir group (mean score, 0.3 [SD, 0.9]) vs the placebo group (mean score, 0.8 [SD, 1.9]) at 12 months ( P = .045) and at 18 months (mean score, 0.2 [SD, 0.9] vs 1.0 [SD, 2.3], respectively; P = .02). There was a decrease in pain duration in the valacyclovir group at 18 months (mean, 13.6 [SD, 11.4] months) vs the placebo group (mean, 18.7 [SD, 29.5] months) (linear mixed-effects model between-group difference, −3.39 months [95% CI, −6.73 to −0.04 months]; P = .046). The total daily dose of neuropathic pain medication was lower in the valacyclovir group (mean, 271.4 [SD, 593.8] mg/d) vs the placebo group (mean, 363.4 [SD, 592.2] mg/d) at 12 months (linear mixed-effects model P = .006) and at 18 months (mean, 209.0 [SD, 412.8] mg/d vs 286.2 [SD, 577.9] mg/d, respectively; linear mixed-effects model P = .01). Conclusions and Relevance One year of suppressive treatment with valacyclovir was associated with a lower dosage of neuropathic pain medication. Participants in the valacyclovir group, who were younger at HZO onset and had a chronic disease duration, had lower pain scores. These secondary outcomes support consideration of 1 year of suppressive treatment with valacyclovir to reduce dosage of pain medications and pain due to HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
P0864 Real-world effectiveness of upadacitinib for perianal Crohn’s disease: A multi-center retrospective study
Quraishi, B, B, Dev, Kline, Meredith R. , Jaiprada, Fnu, Huang, Katherine , Seeraj, Alyssa A., Maas, L.C. , Jajoo, Arpita N., Chowla, Navreet , Stone, Michael D. , Xu, A , Johnson, A. L. , Yarur, Andrés , McCurdy, J, McDonald, Bernard , Wong, Siam Yit, Yarur, Andres J , Devi, Jalpa , Dev, B, Khan, Abdul Wali , Alanazi, S, Maas, L, Stone, M, Patel, Arpan , Shukla, R, Bishu, Shrinivas , Johnson, A L, Parian, Alyssa M. , Mcdonald, B D, Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | January 22, 2025 | Volume: 19 | Issue: Supplement_1 | Pages: i1642-i1644

10.1093/ecco-jcc/jjae190.1038 Get It

Abstract Background There is limited data on the clinical effectiveness of upadacitinib (UPA), an oral selective inhibitor of Janus kinase 1 (JAKi), in patients with perianal Crohn's disease (pCD). The objective of this study was to evaluate the real-world effectiveness of UPA in pCD. Methods This retrospective analysis utilized data on adults (>17 years) who initiated UPA at 45 mg/day for active pCD across 10 centers in the United States and Canada. Standardized data extraction and entry protocols were followed. The primary outcome was clinical response, defined as a ≥3-point reduction in Perianal Disease Activity Index (PDAI) between baseline and follow-up. Secondary outcomes included normalization of CRP (<5 mg/L) or hsCRP (<1 mg/L), clinical remission (PDAI ≤4), and rates of hospitalization, antibiotic use, corticosteroid initiation, and new pCD-related surgeries. Fistula healing on MRI pelvis fistula protocol was defined as an absence of T2-weighted hyperintensity and post-contrast enhancement on T1-weighted images. Predictive analyses used Cox proportional hazards models to evaluate baseline factors influencing time to PDAI remission, including BMI, CRP, albumin, PDAI, pCD disease duration, Montreal location and prior biologic exposure (<2 vs 2+). Results A total of 81 patients were treated with UPA for pCD (median age 35 years and 54.3% male). Most had ileocolonic disease (65.4%), with 54% presenting with complex fistulas. Of these, 92.6% had prior anti-TNF exposure, and 91 (88.9%) had prior exposure to 2+ biologics (Table 1). During a median follow-up of 4 months, clinical response (PDAI) was achieved in 17.3%. Improvement was observed in pain and restriction of activities (27.2%), restriction of sexual activity (13.6%), reduction in number of fistulas (11.1%), degree of induration (11.1%), and discharge (35.8%). Median CRP reduction was 21.05% [IQR: 0.00–74.53], and 21.0% achieved a ≥50% reduction in CRP. MRI healing was limited to 17.7% (6/34). Proctitis decreased from 23.5% at baseline to 7.4% at follow-up. During follow-up, hospitalizations occurred in 9.9%, 14.8% required antibiotics, 8.6% underwent examination under anesthesia in 8.6%, seton placement in 6.2%, and abscess drainage in 6.2%. Patients with ileocolonic disease showed the highest remission (54%) and response (15%) rates, while MRI healing was limited across all Montreal locations (7.4%). Lower baseline CRP (p < 0.05) and PDAI scores (p < 0.01) predicted shorter time to remission. Number of prior biologic exposures (p =0.2) and Montreal location (p = 0.7) were not predictive of time to PDAI remission (Figure 1). Conclusion UPA in a real-world cohort is effective in the management of treatment-refractory pCD. Randomized trials are needed to confirm these observations.
S5 Sustained Improvements in Health-Related Quality of Life Outcomes With Long-Term Risankizumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Results from the FORTIFY Open-Label, Long-Term Extension
Joshi, Namita , Griffith, Jenny, Song, Alexandra , Kim, Brooke, Platt, Andrew M. , Louis, Édouard , Loftus, Edward V. , Peyrin‐Biroulet, Laurent , Ghosh, Subrata , Shukla, Nidhi , Louis, Edouard

Mayo Clinic

American Journal of Gastroenterology | December 9, 2024 | Volume: 119 | Issue: 12S | Pages: S2-S2

10.14309/01.ajg.0001082552.29774.dc Get It

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis
Ball, Somedeb , Feld, Jonathan , Haddadin, Michael , Hawkins, Hayley, Guerra, Veronica , Dworkin, Emily , Tawfiq, Reema, Dulak, Dominika, Feng, Amber , Cotte, Christina , Cohen‐Nowak, Adam , Shukla, Asmita, Winer, Eric S. , Foucar, Charles , Shallis, Rory M. , Im, Annie , Szabo, Aniko, Murthy, Guru Subramanian Guru , Abboud, Ramzi , Patel, Shyam A. , Kishtagari, Ashwin , Balasubramanian, Suresh , Abaza, Yasmin , Lin, Chenyu , Badar, Talha , Patel, Anand , Atallah, Ehab

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3206-3206

10.1182/blood-2024-211623 Get It

Background: Hypomethylating agents (HMA) with venetoclax (VEN) have shown encouraging clinical efficacy in single arm clinical trials for patients with myelodysplastic syndrome (MDS) (Garcia JS et al. ASH 2023, Zeidan AM et al. Am J Hematol. 2023). Many centers have started utilizing HMA-VEN in the clinical management of MDS due to unmet need, pending results of the ongoing phase 3 randomized clinical trial (VERONA) using this combination. However, real world studies with large sample size investigating the use of these agents in MDS, practice patterns and clinical outcomes are lacking. Methods: This is a multicenter retrospective study of 13 US academic medical centers. We included contemporary cohorts of adults (age≥18 years) with MDS who were treated with upfront combination of HMA-VEN, upfront HMA monotherapy, or VEN added after inadequate response or progression on HMA (post-HMA failure VEN). Outcomes analyzed includes clinical response, adverse events (AE) of interest, dose administration and survival. Descriptive statistics were used for baseline characteristics. Overall survival and event free survival (EFS: progression, leukemic transformation, death as events) analysis was conducted using Kaplan-Meier method. Determinants of outcomes were analyzed using multivariable regression models. All analyses were conducted at a significance level of p<0.05. Results: Among 454 patients included, 258 patients received VEN in combination with HMA [upfront HMA-VEN (n=175), post-HMA failure VEN (n=83)] and 196 patients received HMA monotherapy. Median age was 69 (59-77) years and majority of patients had MDS with excess blasts (75%), high risk (31.9%) or very-high (41.8%) risk disease by IPSS-R, 23.7% had therapy related disease, 33% had deletion17p or TP53 mutation and 40.9% underwent allogeneic stem cell transplantation. VEN was predominantly started in outpatient setting (78.6%) with tumor lysis syndrome (TLS) prophylaxis and VEN doses ranged from 70-400mg, adjusted for concomitant antifungal drugs. Incidence of TLS was minimal (No TLS- 92.9%, lab-only TLS 6.2%, 1 pt with clinical TLS). Neutropenic fever was the main AE noted [upfront VEN-HMA (34.2%), HMA monotherapy (22.5%), post-HMA VEN (44.5%)]. In the upfront setting, response rate was significantly higher with HMA-VEN than HMA monotherapy (CR: 33% vs 12%; marrow CR: 40% vs 27%, p<.001). VEN given in the post HMA failure setting also resulted in encouraging response rates (CR 10%, marrow CR 32%). After adjusting for covariates in multivariable analysis, patients treated with HMA-VEN in the upfront setting had significantly improved event free survival as compared to HMA monotherapy (HR 0.59, HR 0.44-0.78, p<0.01), but overall survival did not reach statistical significance (overall survival HR 0.77, 95%CI 0.57-1.04, p=0.08). Conclusions: In this large multicenter retrospective analysis from US academic medical centers, we found that VEN in combination with HMA resulted in encouraging clinical outcomes and was effectively administered in the outpatient setting with minimal TLS. Infection risk management and supportive measures would be important to improve the ability to use this treatment widely, pending results of the ongoing phase 3 randomized clinical trial. Updated results with additional variables will be available at the main meeting.
Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
Annunzio, Kaitlin , Karimi, Yasmin , Luu, Binh, Spurgeon, Stephen E. , Chang, Cheryl , Wan, Zihan, Gathers, Diamone, King, Emily R., Gerhard, Genevieve M. , Armand, Philippe , LaCasce, Ann S. , Vaddaraju, Vedha, Kenkre, Vaishalee P. , Junge, Chase, Stanisic, Alexander V., Zhang, Chen , Ying, Grace W, Gribbin, Caitlin , Ruan, Jia , Shukla, Navika , Smith, Sonali M. , Zelikson, Viktoriya, Williams, Michael, Elghawy, Omar , Schade, Jake , Navalekar, Rohini, Evens, Andrew M. , Danilov, Alexey V. , Fenske, Timothy S. , Stanisic, Alexander , Karimi, Yasmin H , Evens, Andrew M , Stanisic, Alexander V , Wang, Jie , Zhou, Jihao , Wang, Yucai , Muñoz, Javier , Shim, Kevin G. , Moustafa, Muhamad Alhaj , Baidoun, Firas , Epperla, Narendranath , McLane, Michael, Luu, Binh, King, Emily R., Watkins, Marcus P. , Bartlett, Nancy L. , Ryan, Christine E. , Vaddaraju, Vedha , Wallace, Danielle , Junge, Chase, Grover, Natalie S. , Florindez, Jorge A. , Karmali, Reem , Venugopal, Parameswaran , Barta, Stefan K , Matasar, Matthew J.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4406-4406

10.1182/blood-2024-194601 Get It

Introduction: Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) Prognosis is highly variable due to underlying biological and molecular heterogeneity. The first-line (1L) treatment paradigm for MCL continues to evolve with increasing use of bruton tyrosine kinase inhibitors (BTKi) and decreasing use of autologous stem cell transplant (ASCT). TP53 alterations are associated with inferior outcomes in MCL. The aim of this retrospective study is to determine treatment strategies and clinical outcomes in MCL patients based on TP53 gene mutation status. Methods: Retrospective data were collected from 19 institutions in the United States from 1/1993 to 1/2024. We examined treatment patterns and outcomes among MCL patients >18 years of age with known TP53 mutation status by sequencing. Patients who did not receive treatment were excluded. The analysis was stratified based on presence of TP53 mutations. Systemic therapies were categorized as chemo-immunotherapy (CIT), non-chemotherapy (including monoclonal antibodies, lenalidomide, venetoclax, and novel agents on clinical trial), and regimens containing BTKi. The primary outcome was overall survival (OS) and secondary outcomes were progression free survival (PFS) and time to next treatment (TTNT). OS and PFS were estimated with the Kaplan-Meier method and log-rank tests were used to compare groups. Results: 645 patients were included in the study, with 468 men (72.6%) and median age was 64 years (range 30-89). 230/645 patients (35.7%) had a TP53 mutation, of which 182 (79%) were identified prior to 1L. While the male/female distribution was the same between the mutated and unmutated groups, median age at diagnosis and MIPI risk score was higher in the TP53 mutated group (age 65.9 vs 63.1 yrs, p= 0.015; MIPI 6.4 vs 6.1, p<0.001). TP53 unmutated patients had a median of 1 line of therapy vs. 2 for the mutated group (p<0.001, range 1-8). Blastoid histology and higher ki67 were also associated with the TP53 mutated group (p=0.045, 0.01 respectively) The median OS was 14.2 years for TP53 unmutated and 8.3 years for TP53 mutated patients (p<0.0001). PFS in 1L was 0.95 years in TP53 mutated compared to 2.02 years in TP53 unmutated group (p<0.0001). Selection of 1L therapeutic strategy was not associated with presence of TP53 mutation (Χ2 p= 0.21) although more patients in the TP53 unmutated group underwent ASCT (119/415 vs 38/230; Χ2 p=0.0006) TP53 mutation was associated with inferior survival compared to TP53 unmutated patients for CIT in 1L but the difference did not reach statistical significance when non-chemotherapy regimens and regimens containing BTKi were used. For CIT in 1L, 5 year OS was 78% [71-84%] for unmutated compared to 58% [48-67%] for the mutated group (p=0.0001 ). For non-chemotherapy regimens, 5 year OS for unmutated patients was 73% [52- 86%] compared to 52% [25-73%] for the mutated group (p=0.09). For regimens containing BTKi, 5 year OS for unmutated was 93% [81-97%] compared to 57% [28-78%] for mutated (p=0.07). Within the TP53 mutated group, there were no differences in any clinical outcomes between those receiving CIT, non-chemotherapy, or BTKi in 1L. While median OS appeared numerically longer in the BTKi group (14.4 yrs vs 8.8 yrs for CIT and 6.8 yrs for non-chemotherapy), the difference did not reach statistical significance (p=0.58). In contrast,TP53 unmutated patients who received CIT in 1L had better TTNT (p=0.0039) compared to those in non-chemotherapy and BTKi groups. There was no improvement in PFS (p=0.79) or OS (p=0.47). Conclusions To our knowledge this is the largest retrospective real world dataset of MCL treatment outcomes stratified by TP53 mutation. As in prior studies, TP53 mutation portends a worse prognosis in MCL compared to TP53 unmutated patients, but outcomes are better than historically reported. CIT in 1L was not associated with improved OS in either group. Irrespective of TP53 mutation status, incorporation of BTKi in first line was not associated with improved clinical outcomes. The gap in OS between TP53 mutated and unmutated MCL may be narrowing as treatment paradigms shift away from intensive induction chemotherapy and ASCT, and due to an increasing number of effective therapies for relapsed patients. Clinical trials of novel agents are needed to further improve the OS of TP53 mutated MCL patients.
Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
Epstein‐Peterson, Zachary D. , Joseph, Ashlee , Drill, Esther , Brooks, Taylor , Chong, Emeline R. , Cruz, Jamie Dela , Frank, Matthew J. , Jacobson, Caron A. , Maddocks, Kami J. , Sauter, Craig S. , Shukla, Navika , Stanisic, Alexander V., Therwhanger, Dylan , Besien, Herman van, Yamshon, Samuel , Palomba, Maria Lia, Kumar, Anita J. , Stanisic, Alexander , Brooks, Taylor R , Stanisic, Alexander V , Lionel, Anath C. , Atallah‐Yunes, Suheil Albert , Chong, Elise A. , Ip, Andrew , Iqbal, Madiha , Kamdar, Manali , Karmali, Reem , Matasar, Matthew J. , Merryman, Reid W. , Muñoz, Javier , Riedell, Peter A. , Ryan, Christine E. , Salles, Gilles , Sawalha, Yazeed , Shouval, Roni , Wang, Yucai , Zelenetz, Andrew D. , Palomba, M. Lia , Jain, Preetesh

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 238-238

10.1182/blood-2024-192995 Get It

Background: CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy is an established treatment with high efficacy in treating relapsed or refractory (R/R) mantle cell lymphoma (MCL). However, with CAR-T therapy, refractory disease occurs and a continuous pattern of relapse over time has been observed. Limited data exist about post-CAR-T progression of disease (POD) management and outcomes in MCL. Such data would meaningfully inform practice and set a critical benchmark for future studies in the post-CAR-T setting. We characterized treatment patterns and outcomes for pts with POD after CD19 CAR-T therapy for R/R MCL. Methods: We queried institutional databases to identify pts with R/R MCL who received CD19-directed CAR-T therapy. Treatment may have occurred as standard-of-care or in a clinical trial. We performed chart review to extract variables and categorized therapies by mechanism(s) of action. We used descriptive statistics to characterize patient/disease characteristics and treatment patterns, the reverse Kaplan-Meier method to calculate follow-up, the Kaplan-Meier method to calculate survival, and Cox proportional hazards to associate clinical and disease features with survival outcomes. Results: Across 9 sites, we identified 306 pts who received CD19 CAR-T for R/R MCL, of which 104 (34%) experienced POD and were investigated in detail: pts with POD were mostly men (73%), had a median age of 67 yrs (range 36-86) at infusion, and had received a median of 3 lines of therapy pre-leukapheresis, including a BTK inhibitor (BTKi) in 97% of patients; 36% of BTKi-exposed patients had BTKi-unresponsive disease. High-risk tumor features were common pre-CAR-T: 47/68 (69%) with a TP53 mutation, 66/93 (71%) with Ki67 ≥50%, and 47/102 (46%) with blastoid/pleomorphic MCL. Most pts (75%) received bridging therapy. Pts received brexucabtagene autoleucel (88%) or lisocabtagene maraleucel (12%). Regarding best CAR-T response for pts with POD, 71% had a complete response (CR), 13% partial response (PR), and 15% had no response. The median time from CAR-T infusion to POD was 6 months (IQR 3-12). At time of POD, high-risk MCL features were again common: 55% blastoid/pleomorphic, 42/56 (75%) Ki67 ≥50%, 51/83 (61%) MIPIb high-risk, and 21/35 (60%) TP53-mutated MCL. Among 69 pts with CD19 assessed on a post-POD biopsy, 8 (12%) had CD19-negative disease. 30% of pts had an ECOG performance status of ≥2 at time of POD. After POD occurred, 15 pts received no anti-lymphoma therapy (Tx), 11 pts underwent excision or radiation, and 78 pts received systemic therapy. The most commonly used first-line systemic Tx post-CAR-T progression included: pirtobrutinib in 13 pts [overall response rate (ORR) 31%], chemoimmunotherapy in 12 pts (ORR 25%), venetoclax in 10 patients (ORR 20%), bispecific antibodies (BsAb) in 10 pts (ORR 60%), and small molecule combinations (at least 2 of BTK inhibitor, BCL2 inhibitor, and lenalidomide) in 8 patients with ORR 50%. The ORR to all first systemic Tx post-POD was 42%. The median follow-up from POD is 15.2 months among survivors. The median progression-free and overall survival (OS) from time of POD were 2.3 (95% CI 1.9-3.4) and 5.4 months (95% CI 4.5-9.4), respectively, and 1-year OS rate was 33%. TP53 mutations predicted inferior OS (HR 2.83, 95% CI 1.08-7.43, P = 0.026) as did age ≥65 years at time of POD (HR 1.83, 95% CI 1.07-3.15, P = 0.023), MIPIb high-risk (HR 3.56, 95% CI 1.08-11.7, P = 0.042), and non-response to CAR-T (HR 3.55, 95% CI 1.93-6.53, P < 0.001). Discussion: Our data, the largest reported cohort of pts with POD post-CAR-T with R/R MCL, confirm the poor prognosis in this patient population, with a median OS of 5.4 months. BsAbs showed promise with an overall response rate of 60%. The presence of a TP53 mutation significantly predicted inferior OS, corroborating the prognostic importance of this finding in the post-CAR-T context. Data from pts treated at additional sites and updated analyses will be presented at the meeting.
S1288 Real-World Effectiveness of Ozanimod for Ulcerative Colitis in Patients With Prior Advanced Therapy Exposure: A Multicenter Study
Scalzo, Nicholas , Lieto, Stephen, Huang, Katherine , Xu, Anthony , Rajauria, Palak , Ayoub, Malek , Johnson, Amanda M. , Yarur, Andrés , Dulaney, David , Seth, Nikhil , Shukla, Richa, Sokol, Uyen, Sands, Bruce E., Yarur, Andres J , Khan, Abdul Wali , Pekow, Joel , Patel, Anish A , Bishu, Shrinivas , Shukla, Richa, Jain, Anjali , Rubin, David T. , Sands, Bruce E , Deepak, Parakkal , Ungaro, Ryan C.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S921-S921

10.14309/01.ajg.0001034520.61834.16 Get It

Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased α‐Catenin
Osumi, Teruko, Al‐Toubat, Mohammed , Serrano, Samuel, McKenna, Robert W., Chardon‐Robles, Jonathan, Balaji, K.C. , Al-Toubat, Mohammed , Singh, Pankaj Kumar , Shukla, Sanjeev , Singh, Pankaj K. , Mietzsch, Mario , McKenna, Robert, Krishnan, Sunil

Mayo Clinic

The Prostate | October 21, 2024 | Volume: 85 | Issue: 2 | Pages: 156-164

10.1002/pros.24812 | PMID 39428693 Get It

AbstractBackgroundThe E‐cadherin, α‐ and β‐Catenin interaction at the cell adherens junction plays a key role in cell adhesion; alteration in the expression and function of these genes are associated with disease progression in several solid tumors including prostate cancer. The membranous β‐Catenin is dynamically linked to the cellular cytoskeleton through interaction with α‐Catenin at amino acid positions threonine 120 (T120) to 151 of β‐Catenin. Nuclear presence of α‐Catenin modulates the sensitivity of cells to DNA damage. The objective of this study is to determine the role of α‐Catenin and protein kinase D1 (PrKD1) in DNA damage response.MethodsProstate cancer cells; LNCaP, LNCaP (Sh‐PrKD1; silenced PrKD1), C4‐2 and C4‐2 PrKD1 were used for various sets of experiments to determine the role of DNA damage in PrKD1 overexpression and silencing cells. These cells were treated with compound‐10 (100 nM) and Etoposide (30 µM), total cell lysates, cytosolic and nuclear fractions were prepared to observe various protein expressions. We performed single cell gel electrophoresis (COMET assay) to determine the etoposide induce DNA damage in C4‐2 and C4‐2 PrKD1 cells. The animal experiments were carried out to determine the tolerability of compound‐10 by mice and generate preliminary data on efficacy of compound‐10 in modulating the α‐Catenin and PrKD1 expressions in inhibiting tumor progression.ResultsPrKD1, a novel serine threonine kinase, phosphorylates β‐Catenin T120. In silico analysis, confirmed that T120 phosphorylation alters β‐ to α‐Catenin binding. Forced expression of PrKD1 in prostate cancer cells increased β‐ and α‐Catenin protein levels associated with reduced etoposide induced DNA damage. Downregulation of α‐Catenin abrogates the PrKD1 mitigation of DNA damage. The in vitro results were corroborated in vivo using mouse prostate cancer patient derived xenograft model by inhibition of PrKD1 kinase activity with compound‐10, a selective PrKD inhibitor, demonstrating decreased total β‐ and α‐Catenin protein levels, and β‐Catenin T120 phosphorylation.ConclusionsAlteration in DNA damage response pathways play major role in prostate cancer progression. The study identifies a novel mechanism of α‐Catenin dependent DNA damage mitigation role for PrKD1 in prostate cancer.
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
Fornaro, Marco , Venerito, Vincenzo , Pellico, Maria Rosa , Iannone, Florenzo , Joshi, Mrudula , Chen, Yi‐Ming , Tan, Ai Lyn , Saha, Sreoshy , Chatterjee, Tulika , Agarwal, Vishwesh , Kadam, Esha , Hasan, A T M Tanveer , Shumnalieva, Russka , Milchert, Marcin , Tan, Chou Luan , Vaidya, Binit , Kuwana, Masataka , Shaharir, Syahrul Sazliyana , Tehozol, Erick Adrian Zamora , Gutiérrez, Carlos Enrique Toro , Goo, Phonpen Akawatcharangura , Katchamart, Wanruchada , Parodis, Ioannis , Nikiphorou, Elena , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, CoVAD Study, Sen, Parikshit, Javaid, Mahnoor, Andreoli, Laura, Lini, Daniele, Schreiber, Karen, Nune, Arvind, Tan, Ai Lyn, Patel, Aarat, Pauling, John D, Wincup, Chris, Barman, Bhupen, Torre, Ignacio García-De La, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Kibbi, Lina El, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Griger, Zoltán, Kardes, Sinan, Vince, Melinda Nagy, Singh, Yogesh Preet, Ranjan, Rajiv, Jain, Avinash, Pandya, Sapan C, Pilania, Rakesh Kumar, Sharma, Aman, M, Manesh Manoj, Gupta, Vikas, Kavadichanda, Chengappa G, Patro, Pradeepta Sekhar, Ajmani, Sajal, Phatak, Sanat, Goswami, Rudra Prosad, Chowdhury, Abhra Chandra, Mathew, Ashish Jacob, Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj, Pande, Arunkumar R, Chandwar, Kunal, Ghodke, Akanksha, Boro, Hiya, Fazal, Zoha Zahid, Vaidya, Binit, Cansu, Döndü Üsküdar, Yıldırım, Reşit, Gasparyan, Armen Yuri, Papa, Nicoletta Del, Sambataro, Gianluca, Fabiola, Atzeni, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Angelis, Rossella De, Danieli, Maria Giovanna, Grignaschi, Silvia, Giollo, Alessandro, Alunno, Alessia, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, Loarce-Martos, Jesús, Prieto-González, Sergio, Gonzalez, Raquel Aranega, Yoshida, Akira, Nakashima, Ran, Sato, Shinji, Kimura, Naoki, Kaneko, Yuko, Gono, Takahisa, Tomaras, Stylianos, Proft, Fabian Nikolai, Holzer, Marie-Therese, Gromova, Margarita Aleksandrovna, Aharonov, Or, Griger, Zoltán, Hmamouchi, Ihsane, bouchti, Imane El, Baba, Zineb, Giannini, Margherita, Maurier, François, Campagne, Julien, Meyer, Alain, Langguth, Daman, Limaye, Vidya, Needham, Merrilee, Srivastav, Nilesh, Hudson, Marie, Landon-Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Arbeláez, Álvaro, Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico, Zimba, Olena, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Airenakho, Emorinken, Madu, Nwankwo Henry, Yerima, Abubakar, Olaosebikan, Hakeem, Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Ugarte-Gil, Manuel Francisco, Chinchay, Lyn, Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A, Harifi, Ghita, Fuentes-Silva, Yurilís, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio, Bautista, Generoso Guerra, Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, M, Cristian Vergara, Báez, Jossiell Then, Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Salinas, Rodrigo García, Obiols, Alejandro Quiñónez, Chávez, Nilmo, Ordóñez, Andrea Bran, Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina, Hidalgo, Eduardo Romero, Saenz, Ricardo, M, Idania Escalante, Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Pauling, John D , Wincup, Chris , Sambataro, Gianluca , Angelis, Rossella De , Loarce‐Martos, Jesus , Lini, Daniele , Fuentes-Silva, Yurilís , Giollo, Alessandro , Grignaschi, Silvia , Schreiber, Karen , Danieli, Maria Giovanna , Gupta, Latika , Shinjo, Samuel Katsuyuki , Hoff, Leonardo Santos , Kadam, Esha , Ziade, Nelly , Velikova, Tsvetelina , Hasan, A T M Tanveer , Shumnalieva, Russka , Milchert, Marcin , Tan, Chou Luan , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Vaidya, Binit , Kuwana, Masataka , Sazliyana Shaharir, Syahrul , Knitza, Johannes , Makol, Ashima , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , Halabi, Hussein , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Distler, Oliver , Katchamart, Wanruchada , Day, Jessica , Parodis, Ioannis , Nikiphorou, Elena , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika , Joshi, Mrudula , Agarwal, Vishwesh , Tan, Ai Lyn , Chatterjee, Tulika , Pauling, John D , Wincup, Chris , Chen, Yi-Ming , Saha, Sreoshy , De Angelis, Rossella , Iannone, Florenzo , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Makol, Ashima , Halabi, Hussein , Dey, Dzifa , Caballero‐Uribe, Carlo V. , Distler, Oliver , Day, Jessica , Group, CoVAD Study, Sen, Parikshit, Javaid, Mahnoor, Andreoli, Laura, Nune, Arvind, Tan, Ai Lyn, Patel, Aarat, Barman, Bhupen, Torre, Ignacio García-De La, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Kibbi, Lina El, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Griger, Zoltán, Kardes, Sinan, Vince, Melinda Nagy, Singh, Yogesh Preet, Ranjan, Rajiv, Jain, Avinash, Pandya, Sapan C, Pilania, Rakesh Kumar, Sharma, Aman, M, Manesh Manoj, Gupta, Vikas, Kavadichanda, Chengappa G, Patro, Pradeepta Sekhar, Ajmani, Sajal, Phatak, Sanat, Goswami, Rudra Prosad, Chowdhury, Abhra Chandra, Mathew, Ashish Jacob, Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj, Pande, Arunkumar R, Chandwar, Kunal, Ghodke, Akanksha, Boro, Hiya, Fazal, Zoha Zahid, Vaidya, Binit, Cansu, Döndü Üsküdar, Yıldırım, Reşit, Gasparyan, Armen Yuri, Papa, Nicoletta Del, Fabiola, Atzeni, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Alunno, Alessia, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, Prieto-González, Sergio, Gonzalez, Raquel Aranega, Yoshida, Akira, Nakashima, Ran, Sato, Shinji, Kimura, Naoki, Kaneko, Yuko, Gono, Takahisa, Tomaras, Stylianos, Proft, Fabian Nikolai, Holzer, Marie-Therese, Gromova, Margarita Aleksandrovna, Aharonov, Or, Griger, Zoltán, Hmamouchi, Ihsane, bouchti, Imane El, Baba, Zineb, Giannini, Margherita, Maurier, F. , Campagne, Julien, Meyer, Alain , Langguth, Daman, Limaye, Vidya, Needham, Merrilee, Srivastav, Nilesh, Hudson, Marie, Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Arbeláez, Álvaro, Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico, Zimba, Olena, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Airenakho, Emorinken, Madu, Nwankwo Henry, Yerima, Abubakar, Olaosebikan, Hakeem, Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Ugarte-Gil, Manuel Francisco, Chinchay, Lyn, Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio, Bautista, Generoso Guerra, Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, M, Cristian Vergara, Báez, Jossiell Then, Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Salinas, Rodrigo García, Obiols, Alejandro Quiñónez, Chávez, Nilmo, Ordóñez, Andrea Bran, Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina, Hidalgo, Eduardo Romero, Saenz, Ricardo, M, Idania Escalante, Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela

Mayo Clinic

Rheumatology | September 26, 2024 | Volume: 64 | Issue: 4 | Pages: 2133-2142

10.1093/rheumatology/keae520 | PMID 39324556 Get It

Abstract Objective The presence of comorbidities can substantially affect patients’ quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited. Methods We examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs) and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined basic multimorbidity (BM) as the presence of ≥2 non-rheumatic chronic conditions and complex multimorbidity (CM) as the presence of ≥3 non-rheumatic chronic conditions affecting ≥3 organ systems. Hierarchical clustering on principal components was performed for grouping. Results Among the COVAD respondents, 1558 IIMs, 4591 oAIRDs and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (odds ratio [OR]: 1.62 vs oAIRDs and 2.95 vs HCs, P < 0.01), BM (OR: 1.66 vs oAIRDs and 3.52 vs HCs, P < 0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, P < 0.01) and mental health disorders (MHDs) (OR: 1.33 vs oAIRDs and 2.63 vs HCs, P < 0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all P < 0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores. Conclusion Patients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.